An interesting finding of our study, however, is that the effect of extended aromatase inhibition on adapted disease-free survival differed between patients with tumours expressing both the oestrogen and progesterone receptor and patients with tumours expressing only one hormone receptor. Here, NR4A1 is linked to neoplasm.